Targeting the PI3K pathway in cancer: are we making headway?

Filip Janků; Timothy A. Yap; Funda Meric‐Bernstam

doi:10.1038/nrclinonc.2018.28

Keywords

PI3K/AKT/mTOR pathwayMedicineTemsirolimusIdelalisibEverolimusClinical trialCancerProtein kinase BPharmacologyCancer researchOncologyBioinformaticsDiscovery and development of mTOR inhibitorsInternal medicineSignal transductionBiology

Affiliated Institutions

The University of Texas MD Anderson Cancer Center US

Related Publications

Targeting PI3K/Akt signal transduction for cancer therapy

Yan He , Miao Sun , Guo Geng Zhang +4 more

The phosphatidylinositol 3-kinase (PI3K)/Akt pathway plays a crucial role in various cellular processes and is aberrantly activated in cancers, contributing to the occurrence an...

2021 Signal Transduction and Targeted Therapy 1437 citations

Targeting PI3K in cancer: mechanisms and advances in clinical trials

Jing Yang , Ji Nie , Xuelei Ma +3 more

Phosphatidylinositol-3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) signaling is one of the most important intracellular pathways, which can be considered as a master ...

2019 Molecular Cancer 1491 citations

Alternative rapamycin treatment regimens mitigate the impact of rapamycin on glucose homeostasis and the immune system

Sebastian I. Arriola Apelo , Joshua C. Neuman , Emma L. Baar +6 more

Inhibition of the mechanistic target of rapamycin (mTOR) signaling pathway by the FDA-approved drug rapamycin has been shown to promote lifespan and delay age-related diseases i...

2015 Aging Cell 174 citations

Molecular Target Class Is Predictive of <i>In vitro</i> Response Profile

Joel Greshock , Kurtis E. Bachman , Yan Degenhardt +9 more

Abstract Preclinical cellular response profiling of tumor models has become a cornerstone in the development of novel cancer therapeutics. As efforts to predict clinical efficac...

2010 Cancer Research 123 citations

Transcriptional Pathway Signatures Predict MEK Addiction and Response to Selumetinib (AZD6244)

Jonathan R. Dry , Sandra Pavey , Christine A. Pratilas +26 more

Abstract Selumetinib (AZD6244, ARRY-142886) is a selective, non–ATP-competitive inhibitor of mitogen-activated protein/extracellular signal–regulated kinase kinase (MEK)-1/2. Th...

2010 Cancer Research 259 citations

Publication Info

Year: 2018
Type: review
Volume: 15
Issue: 5
Pages: 273-291
Citations: 1000
Access: Closed

External Links